Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Emtansine Extension Study
NCT00781612Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Oct 2008
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 35
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in metastatic neoplasm, sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 18 years and Percentage of Participants With Adverse Events Leading to Study Treatment Discontinuation or Dose Reduction up to 18 years. Started Oct 2008; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
metastatic neoplasm
Beyond the preview
Go deeper on NCT00781612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781612.